Core Viewpoint - The successful mass production of Scandium-44 (Sc-44) in China marks a significant advancement in the field of radiopharmaceuticals, providing a higher resolution and more convenient imaging agent for tumor diagnosis and treatment [1][3]. Group 1: Production Process - The research team at the Jinan Institute of Nuclear Technology has achieved the production of Sc-44 with an activity level in the hundred millicurie range and a nuclear purity greater than 99% [1]. - The production process involves using a cyclotron to bombard natural calcium nitrate targets, resulting in the extraction of Sc-44 from calcium-44 [3]. - The team innovated the target preparation process and developed a purification workflow, conducting over 50 full-process experiments and thousands of data simulations over 700 days [5]. Group 2: Comparison with Existing Isotopes - Currently, the most commonly used radioactive isotope in clinical settings is Fluorine-18 (F-18), which has a half-life of only 110 minutes, necessitating immediate production and delivery [9]. - Gallium-68 (Ga-68), another commonly used isotope, has a half-life of 68 minutes and is limited to on-site preparation or short-distance transport [9]. - In contrast, Sc-44 has a half-life of approximately 4.04 hours, allowing for more flexible production and distribution, making it a superior imaging agent [11]. Group 3: Advantages of Sc-44 - Sc-44 offers higher imaging quality due to its lower positron energy compared to Ga-68, making it a more effective tool for tumor detection [11]. - As a metal element, Sc-44 can easily be labeled with various types of drugs, including peptides, antibodies, and small molecules, enhancing its versatility in pharmaceutical applications [11]. - The production process for Sc-44 is compatible with most accelerators used in hospitals, and the raw material costs are low, positioning China to compete with international standards in Sc-44 drug development [11].

Group 1 - The State Administration for Market Regulation has approved the establishment of China's first national standard device for β radiation tissue absorption dose, developed by the China Institute of Metrology Science, aimed at improving measurement standard accuracy in fields such as radiological medicine and nuclear safety [1] - China Dongfang (01763.HK), as a company related to nuclear medicine, may benefit indirectly from the industry's technological upgrades, but attention should be paid to the actual impact of subsequent policy implementation on its business [1] Group 2 - In the recent trading period from February 5 to February 11, 2026, China Dongfang's stock price increased by 1.48%, but exhibited significant volatility, with a drop of 2.23% on February 5 and a further decline of 1.42% on February 6, followed by rebounds of 3.18% and 2.33% on February 9 and 10, respectively, and a slight decrease of 0.27% to HKD 21.88 on February 11 [2] - Technical indicators show that the MACD histogram turned negative on February 11 (-0.113), while the KDJ indicator rose from the oversold region to 54.19, indicating short-term fluctuations; additionally, there has been a continuous net outflow of funds, with a net outflow of HKD 848,900 on February 11, reflecting some profit-taking by investors [2]

Core Viewpoint - China Tongfu (01763) has achieved domestic large-scale production of the radioactive nuclide Gallium-68 (Ge-68) using a 30MeV proton cyclotron, meeting commercial product standards in Europe and the US, marking a significant advancement in the country's nuclear medicine capabilities [1] Group 1: Company Developments - The successful production of Ge-68 signifies that China now possesses the ability for stable and independent large-scale manufacturing of this critical nuclide, which is essential for the production of Gallium-68 used in PET imaging for tumor diagnosis [1] - Atom High-Tech will continue to focus on the nuclear medicine sector, increasing investment in the research and development of nuclide drugs and technological innovation to support the development of precision medicine [1] Group 2: Industry Implications - Ge-68 is the parent nuclide of Gallium-68, which decays to produce Gallium-68, a key component in radiopharmaceuticals for tumor imaging, providing crucial diagnostic information for cancer treatment [1] - There are currently 13 Gallium-68 drugs in clinical trials in China, with several already approved for use in cancer diagnosis abroad, indicating a broad market potential for Ge-68 in both domestic and international markets [1]

Core Viewpoint - China Tongfu (01763) has achieved domestic large-scale production of the radioactive nuclide Gallium-68 precursor, Germanium-68, marking a significant advancement in the country's nuclear medicine capabilities [1] Group 1: Company Developments - Atomic High-Tech Co., Ltd. has successfully utilized a 30MeV proton cyclotron to produce Germanium-68, meeting commercial product standards required by Europe and the United States [1] - This achievement indicates that China now possesses a stable and independent production capacity for Germanium-68, which is crucial for the precise diagnosis and treatment of cancer patients [1] Group 2: Industry Implications - Germanium-68 is the parent nuclide of Gallium-68, which decays to produce Gallium-68 used in PET imaging for tumor diagnosis, providing essential support for clinical cancer treatment [1] - There are currently 13 Gallium-68 drugs in clinical trials in China, with several already approved for use abroad, highlighting a broad market potential for Germanium-68 in both domestic and international markets [1] - The company plans to continue focusing on the nuclear medicine sector, increasing investment in the research and development of nuclide drugs to support the advancement of precision medicine and enhance public health [1]

Core Viewpoint - China Tongfu (01763.HK) announced that its subsidiary, Atomic High-Tech Co., has successfully achieved the domestic large-scale production of the radioactive nuclide Gallium-68 (Ge-68) using a 30MeV proton cyclotron, meeting commercial product standards in Europe and the U.S. This development signifies China's capability for stable and independent production of Ge-68, which is crucial for precise diagnosis and treatment of cancer patients [1][2]. Group 1 - Atomic High-Tech has become one of the few companies globally to master the large-scale preparation technology of Ge-68, which is the parent nuclide of Gallium-68 [1]. - Gallium-68 labeled radiopharmaceuticals are essential in nuclear medicine for PET imaging, providing significant support for clinical diagnosis and treatment of tumors [1]. - There are currently 13 Gallium-68 drugs in clinical trials in China, with several foreign counterparts already approved for cancer diagnosis, indicating a broad market potential for Ge-68 [1]. Group 2 - The company plans to continue focusing on the nuclear medicine field, increasing investment in the research and development of radiopharmaceuticals and technological innovation to support the development of precision medicine [2]. - The commitment to enhancing product quality and services aims to strengthen healthcare for the public [2].

Group 1 - The core theme of the recent municipal meetings is "enhancing capability," which encompasses not only growth in scale and speed but also the restructuring of development momentum, industrial structure, and competitive positioning [2] - This year marks the beginning of the "14th Five-Year Plan," and the strategy for "enhancing capability" outlines a clear path for promoting high-quality regional economic development [2] Group 2 - Building a modern industrial system is identified as a primary task across various regions, focusing on strengthening advantageous industries, exploring the potential of traditional manufacturing, and establishing brand recognition for emerging and specialty industries [3] - Yibin has experienced a 60% growth in industrial added value over the past five years, with its power battery industry leading nationally and its photovoltaic industry ranking first in the province [5] - In 2025, despite industry pressures, Yibin's photovoltaic industry is projected to reach a scale of 37 billion yuan, reflecting a year-on-year growth of 28.5% [5] Group 3 - Nanchong is focusing on upgrading traditional manufacturing through quality improvement and strengthening supply chains, with a significant milestone achieved in the production of a new model of commercial vehicles [6] - Nanchong has 219 enterprises in the automotive and parts industry, and it plans to accelerate the construction of a circular economy industrial park to address gaps in mechanical manufacturing [6] Group 4 - Leshan is restructuring its industrial landscape through systematic layout and strengthening industrial chains, aiming to stabilize its advantageous industries while enhancing the support of specialty industries [7] - The city is promoting the development of photovoltaic energy storage and green chemical industries, while also extending the application of nuclear technology in various sectors [7] Group 5 - Luzhou is focused on cultivating competitive specialty industrial clusters, particularly in nuclear medicine, and aims to establish itself as a "nuclear medicine application demonstration city" [8] - Aba Prefecture is prioritizing ecological development and unique resource advantages, with plans to build clean energy bases and a modern seed industry park [8] Group 6 - Innovation and openness are seen as essential for enhancing capability, with discussions on topics like "new integration" and "external openness" being prominent at the municipal meetings [9] - Deyang is integrating technological and industrial innovation, with a focus on the equipment manufacturing sector and the establishment of innovation platforms [10] - Meishan is advancing the integration of new technologies and has established numerous pilot research platforms to facilitate the transformation of scientific achievements [10][11] Group 7 - Meishan has over 560 technology-driven enterprises, emphasizing the role of small and medium-sized tech companies in driving industrial transformation [11] - Both Leshan and Meishan are prioritizing the construction of transportation and logistics hubs as a breakthrough for enhancing openness [11]

Core Viewpoint - The article highlights the achievements of researcher Di Cuixia in the field of heavy ion cancer therapy, emphasizing her innovative contributions and dedication to bridging basic research with clinical needs [1][3]. Group 1: Career Development - Di Cuixia transitioned from a background in plant science to tumor radiotherapy, leveraging her expertise in antibody preparation to make significant strides in cancer research [2][3]. - After returning to China in 2010, she joined the Institute of Modern Physics at the Chinese Academy of Sciences, focusing on heavy ion therapy, which was emerging as a leading technology in cancer treatment [2][3]. Group 2: Research Focus - Di Cuixia's research centers on the mechanisms of heavy ion-induced apoptosis in cancer cells, expanding into areas such as radiation sensitizers, overcoming radiotherapy resistance, and personalized radiotherapy [3][4]. - She has successfully secured multiple research grants, including projects from the National Natural Science Foundation and the Ministry of Science and Technology, to support her innovative research [3][4]. Group 3: Clinical Collaboration - Di Cuixia emphasizes the importance of aligning basic research with clinical needs, actively seeking collaborations with hospitals to obtain clinical samples and data [3][4]. - Her efforts have led to strong partnerships with institutions like Lanzhou University First Hospital and the Cancer Hospital of the Chinese Academy of Medical Sciences, facilitating joint research initiatives [4][5]. Group 4: Innovations and Achievements - Di Cuixia has identified the issue of radiotherapy resistance as a critical challenge and is developing radiation sensitizers to enhance the efficacy of conventional radiotherapy [5]. - Preliminary results indicate that these sensitizers can increase tumor cell sensitivity to conventional radiation, potentially addressing a significant barrier in cancer treatment [5]. Group 5: Outreach and Education - In addition to her research, Di Cuixia is committed to science popularization, engaging with schoolchildren to inspire interest in science through hands-on experiments and relatable explanations [6]. - She believes in the vast potential for growth in the field of nuclear medicine in China, where only 20-30% of cancer patients currently receive radiotherapy compared to 70% in the United States [6].

Group 1 - The event held in Taicang City focused on promoting the standardized application of nuclear technology in disease diagnosis, targeted therapy, and efficacy evaluation, aiming for equitable access to quality nuclear medical resources [1] - The "One County, One Department" strategic research platform for nuclear medicine aims to provide comprehensive solutions for the establishment of nuclear medicine departments in grassroots hospitals, supporting the implementation of the "One County, One Department" strategy [1] - The AI innovation platform for nuclear medicine research wards will enhance clinical research quality and efficiency through AI-enabled solutions for clinical trials, radiomics research, and patient follow-up management [1] Group 2 - The establishment of the Kunrun Shengyan (Suzhou) Technology Co., Ltd. in Shaxi is expected to inject strong momentum into the growth of the local biopharmaceutical industry, leveraging its comprehensive core competencies across software, intelligent hardware, algorithms, and data [2] - Kunrun Shengyan is recognized as a major scientific research achievement transformation enterprise under the national "863" program, filling multiple technological gaps in the industry [2]

Core Viewpoint - China Tongru (01763) announced that the project "Establishment of a Multimodal Nuclear Medicine Molecular Imaging System for Pediatric Neuroblastoma," involving Yuanzi Gaoke Co., Ltd., won the first prize at this year's Beijing Medical Science and Technology Awards [1] Group 1: Project Overview - Neuroblastoma is the most common extracranial solid tumor in children, accounting for approximately 8%-10% of pediatric malignant tumors and leading to about 10%-15% of childhood cancer-related deaths [1] - More than half of the patients are classified as high-risk at initial diagnosis, with a poor prognosis and a five-year survival rate of less than 50% [1] - The project focuses on addressing the challenges posed by neuroblastoma, which is referred to as the "king of childhood cancers," and aims to contribute to public health in China [1] Group 2: Technological Achievements - The project has established a complete independent innovation chain from key equipment and core drugs to clinical applications, creating a "multimodal, low-dose, short-duration" precision diagnosis and treatment system for neuroblastoma [1] - Yuanzi Gaoke has developed the positron-emitting radiopharmaceutical sodium fluoride [18F] injection, completed Phase III clinical trials, and successfully registered it, filling a gap in domestic bone imaging radiopharmaceuticals [2] - The company has also led the development of the iodine [123I] sodium solution radiopharmaceutical group standard and collaborated with the Friendship Hospital to provide a basis for standardized production of domestic radiopharmaceuticals [2] Group 3: Strategic Collaboration - Yuanzi Gaoke and the nuclear medicine department of the Friendship Hospital have established a long-term strategic partnership based on the concept of "industry-university-research-medical collaboration" [2] - The collaboration has resulted in significant advancements in radiopharmaceutical supply, research platform construction, and clinical trial promotion [2] - Moving forward, Yuanzi Gaoke will continue to focus on the field of nuclear medicine, increase investment in radiopharmaceutical research and technological innovation, and deepen cooperation with clinical institutions to enhance precision medical development [2]

Core Insights - China Tongfu (01763) announced that the project "Establishment of a Multimodal Nuclear Medicine Molecular Imaging System for Pediatric Neuroblastoma," participated by Atomic High-Tech Co., Ltd., won the first prize at this year's Beijing Medical Science and Technology Awards [1] Group 1: Project Overview - Neuroblastoma is the most common extracranial solid tumor in children, accounting for approximately 8%-10% of pediatric malignant tumors and leading to about 10%-15% of childhood cancer-related deaths [1] - The project focuses on addressing the challenges posed by neuroblastoma, which has a poor prognosis with a 5-year survival rate of less than 50% for high-risk patients [1] - The project aims to establish a complete independent innovation chain for neuroblastoma diagnosis and treatment, utilizing multimodal nuclear medicine molecular imaging technology [1] Group 2: Contributions of Atomic High-Tech - Atomic High-Tech has played a key role in the development of radiopharmaceuticals for neuroblastoma, including the successful registration of sodium fluoride injection, filling a gap in domestic bone imaging radiopharmaceuticals [2] - The company has established a long-term strategic partnership with Friendship Hospital, focusing on collaborative innovation in radiopharmaceutical supply, research platform construction, and clinical trial advancement [2] - Future efforts will include increased investment in radiopharmaceutical research and technology innovation, aiming to enhance precision medicine and safeguard public health [2]